Soterius

Executive Summary

Soterius is a technology-enabled pharmacovigilance (drug safety) and medical affairs service provider founded in 2019 and headquartered in San Francisco. The company combines deep pharmaceutical industry expertise with proprietary AI and data platforms to deliver compliant, efficient, and innovative solutions for clinical and post-marketed drug safety management. Serving clients ranging from top global pharma to niche biotechnology companies, Soterius operates globally with a team of experienced professionals. The pharmacovigilance market is growing due to increasing regulatory requirements and the complexity of drug safety monitoring, positioning Soterius to capture demand for scalable, tech-driven solutions. Its focus on compliance and efficiency aligns with industry trends toward automation and real-world evidence integration, giving it a competitive edge in a fragmented market. With a conviction score of 65 out of 100, Soterius appears well-positioned for steady growth, though as a private company, detailed financials and valuation are not publicly available.

Upcoming Catalysts (preview)

• Q3 2026Adoption of AI-Powered Safety Signal Detection by Major Pharma Clients70% success
• Q1 2027Expansion into New Geographic Markets (e.g., EU, Asia) via Regulatory Partnerships50% success
• Q2 2026Launch of Self-Service Pharmacovigilance Platform for Smaller Biotechs60% success